- Celsion has been off 95% since its failed HEAT trial. Since I've been writing, Celsion has been one of my worst calls.
- I've put CLSN off of my radar for the better part of the last year, but recently have been watching some news items.
- The company acquired EGEN, Inc. and is preparing for another HCC trial with optimized RFA.
- RCW Phase II data seems to look promising as well, but there is still tons of risk here.